Cargando…
Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers
Breast cancer development in BRCA1/2 mutation carriers is a net consequence of cell-autonomous and cell nonautonomous factors which may serve as excellent targets for cancer prevention. In light of our previous data we sought to investigate the consequences of the BRCA-mutation carrier state on RANK...
Autores principales: | Widschwendter, Martin, Burnell, Matthew, Fraser, Lindsay, Rosenthal, Adam N., Philpott, Sue, Reisel, Daniel, Dubeau, Louis, Cline, Mark, Pan, Yang, Yi, Ping-Cheng, Gareth Evans, D., Jacobs, Ian J., Menon, Usha, Wood, Charles E., Dougall, William C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4634624/ https://www.ncbi.nlm.nih.gov/pubmed/26629528 http://dx.doi.org/10.1016/j.ebiom.2015.08.037 |
Ejemplares similares
-
Serum RANKL, osteoprotegerin (OPG), and RANKL/OPG ratio in nephrotic children
por: Wasilewska, Anna, et al.
Publicado: (2010) -
Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer
por: Kiechl, Stefan, et al.
Publicado: (2016) -
RANKL/OPG in Breast Cancer — Extending Its Territory to BRCA Mutation Carriers
por: Rachner, Tilman D., et al.
Publicado: (2015) -
Osteoprotegerin and RANKL-RANK-OPG-TRAIL signalling axis in heart failure and other cardiovascular diseases
por: Dutka, Mieczysław, et al.
Publicado: (2021) -
Dysregulation of the RANKL/RANK/OPG axis in thalassemia intermedia patients
por: Alfaqih, Mahmoud A., et al.
Publicado: (2018)